Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$1.63 -5.0%	$1.90	$1.43 ▼ $4.98	$163.17M	1.62	323,142 shs	95,099 shs
ATRA Atara Biotherapeutics	$7.67 +5.8%	$6.63	$5.01 ▼ $18.71	$45.72M	0.32	123,829 shs	138,109 shs
DMAC DiaMedica Therapeutics	$3.87 -3.3%	$4.46	$2.14 ▼ $6.82	$165.85M	1.29	76,839 shs	61,260 shs
LRMR Larimar Therapeutics	$2.10 -21.9%	$2.34	$1.61 ▼ $11.20	$134.46M	0.93	738,315 shs	2.12 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	-0.58%	+0.59%	+3.01%	-37.36%	-28.45%
ATRA Atara Biotherapeutics	-7.29%	-2.29%	+29.70%	-22.04%	-56.72%
DMAC DiaMedica Therapeutics	-5.44%	-13.79%	+14.29%	-33.11%	+33.33%
LRMR Larimar Therapeutics	-9.43%	+14.47%	+37.24%	-26.70%	-65.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.204 of 5 stars	3.5	2.0	0.0	2.0	0.8	1.3
ATRA Atara Biotherapeutics	3.5333 of 5 stars	3.3	2.0	4.7	0.0	2.5	0.6
DMAC DiaMedica Therapeutics	1.6251 of 5 stars	3.5	2.0	0.0	3.2	0.0	0.0
LRMR Larimar Therapeutics	1.6544 of 5 stars	3.6	1.0	0.0	2.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$10.00	515.38% Upside
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	131.42% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$8.00	106.72% Upside
LRMR Larimar Therapeutics	3.10	Buy	$19.63	834.52% Upside

Current Analyst Ratings Breakdown

Latest ATRA, LRMR, ACIU, and DMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/1/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
4/3/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/25/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/25/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00 ➝ $26.00
3/25/2025	LRMR Larimar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $16.00
3/25/2025	LRMR Larimar Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$13.00 ➝ $10.00
3/19/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/14/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/11/2025	ATRA Atara Biotherapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00

(Data available from 5/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$28.30M	5.77	N/A	N/A	$2.12 per share	0.77
ATRA Atara Biotherapeutics	$128.94M	0.35	N/A	N/A	($24.34) per share	-0.32
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$1.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$60.41M	-$0.58	N/A	N/A	N/A	N/A	-28.26%	-18.98%	N/A
ATRA Atara Biotherapeutics	-$276.13M	-$12.97	N/A	N/A	N/A	-132.58%	N/A	-90.16%	5/8/2025 (Estimated)
DMAC DiaMedica Therapeutics	-$19.38M	-$0.60	N/A	N/A	N/A	N/A	-43.67%	-40.81%	5/6/2025 (Estimated)
LRMR Larimar Therapeutics	-$36.95M	-$1.49	N/A	N/A	N/A	N/A	-35.87%	-32.37%	5/8/2025 (Estimated)

Latest ATRA, LRMR, ACIU, and DMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	ACIU AC Immune	-$0.22	N/A	N/A	N/A	$0.32 million	N/A
5/8/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	N/A	N/A	N/A	$4.30 million	N/A
5/8/2025	Q1 2025	LRMR Larimar Therapeutics	-$0.42	N/A	N/A	N/A	N/A	N/A
4/30/2025	Q1 2025	ACIU AC Immune	-$0.22	-$0.21	+$0.01	-$0.21	$1.99 million	$1.12 million
4/30/2025	Q1 2025	LRMR Larimar Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A
3/24/2025	Q4 2024	LRMR Larimar Therapeutics	-$0.29	-$0.45	-$0.16	-$0.45	N/A	N/A
3/17/2025	Q4 2024	DMAC DiaMedica Therapeutics	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A
3/7/2025	Q4 2024	ATRA Atara Biotherapeutics	-$3.82	-$1.19	+$2.63	-$1.19	$20.58 million	$32.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.86	1.86
ATRA Atara Biotherapeutics	N/A	0.59	0.50
DMAC DiaMedica Therapeutics	N/A	11.81	11.81
LRMR Larimar Therapeutics	N/A	13.10	13.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
ATRA Atara Biotherapeutics	70.90%
DMAC DiaMedica Therapeutics	10.12%
LRMR Larimar Therapeutics	91.92%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
ATRA Atara Biotherapeutics	3.70%
DMAC DiaMedica Therapeutics	7.30%
LRMR Larimar Therapeutics	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	94.39 million	Optionable
ATRA Atara Biotherapeutics	330	5.96 million	5.55 million	Optionable
DMAC DiaMedica Therapeutics	20	42.86 million	39.68 million	Optionable
LRMR Larimar Therapeutics	30	64.03 million	61.57 million	Optionable

ATRA, LRMR, ACIU, and DMAC Headlines

Recent News About These Companies

Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 6.40%

May 6 at 6:53 AM | aaii.com

Leerink Partnrs Issues Positive Estimate for LRMR Earnings

May 6 at 1:40 AM | marketbeat.com

Q2 EPS Estimate for Larimar Therapeutics Reduced by Analyst

May 6 at 1:40 AM | marketbeat.com

William Blair Issues Positive Outlook for LRMR Earnings

May 6 at 1:40 AM | marketbeat.com

William Blair Has Optimistic Outlook of LRMR Q2 Earnings

May 6 at 1:37 AM | americanbankingnews.com

Q2 EPS Estimates for Larimar Therapeutics Lowered by Wedbush

May 6 at 1:37 AM | americanbankingnews.com

Leerink Partnrs Issues Optimistic Forecast for LRMR Earnings

May 5 at 1:42 AM | americanbankingnews.com

Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss

May 5 at 12:28 AM | tipranks.com

Brokers Set Expectations for LRMR Q2 Earnings

May 4 at 8:47 AM | marketbeat.com

Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development

May 4 at 5:59 AM | msn.com

What is Wedbush's Forecast for LRMR Q2 Earnings?

May 4 at 2:29 AM | americanbankingnews.com

Larimar Therapeutics (LRMR) Projected to Post Quarterly Earnings on Thursday

May 3 at 6:20 AM | marketbeat.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Acquired by Adage Capital Partners GP L.L.C.

May 1, 2025 | marketbeat.com

Larimar Therapeutics Reports First Quarter 2025 Financial Results

April 30, 2025 | globenewswire.com

Renaissance Technologies LLC Purchases 159,700 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)

April 28, 2025 | marketbeat.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Bought by Blue Owl Capital Holdings LP

April 26, 2025 | marketbeat.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Analysts

April 18, 2025 | marketbeat.com

Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts

April 5, 2025 | seekingalpha.com

Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory Support

March 27, 2025 | msn.com

Larimar Therapeutics price target raised to $16 from $15 at H.C. Wainwright

March 26, 2025 | markets.businessinsider.com

Larimar Therapeutics price target lowered to $10 from $13 at Baird

March 26, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA, LRMR, ACIU, and DMAC Company Descriptions

AC Immune NASDAQ:ACIU

$1.62 -0.09 (-4.97%)

Closing price 03:59 PM Eastern

Extended Trading

$1.67 +0.04 (+2.77%)

As of 07:09 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Atara Biotherapeutics NASDAQ:ATRA

$7.67 +0.42 (+5.79%)

Closing price 04:00 PM Eastern

Extended Trading

$8.33 +0.66 (+8.60%)

As of 07:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

DiaMedica Therapeutics NASDAQ:DMAC

$3.87 -0.13 (-3.25%)

Closing price 03:59 PM Eastern

Extended Trading

$4.14 +0.27 (+6.95%)

As of 07:09 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Larimar Therapeutics NASDAQ:LRMR

$2.10 -0.59 (-21.93%)

Closing price 04:00 PM Eastern

Extended Trading

$2.24 +0.14 (+6.67%)

As of 07:55 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time